Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 2/20 | 0.52 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rotigaptide SCHEMBL20547993 | 0.93 | VHL (0.49) | VHLBDKRB2OPRM1OPRD1NMUR2 | |
| Rotigaptide SCHEMBL20547994 | 0.93 | VHL (0.49) | VHLBDKRB2OPRM1OPRD1NMUR2 | |
| Rotigaptide SCHEMBL29359046 | 0.93 | VHL (0.49) | VHLBDKRB2OPRM1OPRD1NMUR2 | |
| SCHEMBL31327461 | 0.90 | VHL (0.54) | VHLBDKRB2OPRM1OPRD1ACE2 | |
| SCHEMBL19381802 | 0.87 | VHL (0.47) | VHLBDKRB2OPRM1OPRD1 | |
| SCHEMBL16925996 | 0.87 | VHL (0.47) | VHLBDKRB2OPRM1OPRD1 | |
| SCHEMBL25008061 | 0.75 | OPRM1 (0.54) | VHLOPRM1NMUR2NMUR1 | |
| SCHEMBL29871823 | 0.75 | OPRM1 (0.54) | VHLOPRM1 | |
| SCHEMBL29833847 | 0.74 | OPRM1 (0.53) | OPRM1OPRD1 | |
| SCHEMBL29373854 | 0.74 | ACE (0.62) | OPRM1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172848-B2 | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease | University of Pittsburgh—Of the Commonwealth Systems of Higher Education (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172848-B2 | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease | GJA1, VIP, GJB2 | VHL 3141/4885BDKRB2 755/4885OPRM1 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.